December 11, 2019
DirectorsTalk Interviews
Ionis is a drug discovery company that engages in the development and commercialization of ribonucleic acid-targeted the... Read more
Followers on Owler
114
Followers on Owler
Chairman & CEO
Stanley T. Crooke
OVERVIEW
Founded:
1989
Headquarters:
CarlsbadCalifornia
Status:
PublicIndependent Company of NASDAQIONS
Industry Sector:
Pharmaceuticals
Biotechnology
SIC Code:
2834NAICS listing »
2836NAICS listing »
December 11, 2019
DirectorsTalk Interviews
December 11, 2019
MarketScreener
December 12, 2019
DirectorsTalk Interviews
Alnylam is one of Ionis's top competitors. Alnylam was founded in 2002, and its headquarters is in Cambridge, Massachusetts. Like Ionis, Alnylam also works within the Pharmaceuticals sector. Alnylam has 328 more employees than Ionis.
Annual Revenue
$821M
Ionis's revenue is the ranked 1st among it's top 10 competitors. The top 10 competitors average 126.6M. Over the last four quarters, Ionis's revenue has decreased by 12.6%. Specifically, in Q3 2019's revenue was $167.9M; in Q2 2019, it was $163.8M; in Q1 2019, it was $297.2M; in Q4 2018, Ionis's revenue was $192.1M.
No recent acquisitions found related to Ionis
Since Ionis was founded in 1989, it has participated in 4 rounds of funding. In total Ionis has raised $267.2M. Ionis' last funding round was on Jul 2017 for a total of $10.0M
Since Ionis was founded in 1989, it has participated in 4 rounds of funding. In total Ionis has raised $267.2M. Ionis' last funding round was on Jul 2017 for a total of $10.0M
No recent investments found related to Ionis